🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07058987
Starting soon Not applicable

Effects of Enhanced External Counterpulsation Combined With Cardiac Rehabilitation in Patients With Atrial Fibrillation

NCT07058987 · tracked via the Priya Life Science China tracker
Sponsor
Lanzhou University Second Hospital
Phase
Not applicable
Started
2025-07-15
Last updated
2025-07-14

Condition(s) studied

Atrial Fibrillation (AF)Heart Failure (HF)Cardiac Rehabilitation

Investigational drug(s) / intervention(s)

Cardiac Rehabilitation Combined With EECPRoutine Medical Care

Cardiac Rehabilitation Combined With EECP: This intervention consists of a comprehensive cardiac rehabilitation program that includes individualized aerobic exercise training, health education, psychological support, and lifestyle counseling, combined with enhanced external counterpulsation (EECP) therapy administered according to standard cardiovascular protocols. The combined intervention is designed to improve cardiac function, exercise tolerance, and quality of life in patients with atrial fibrillation.

Routine Medical Care: Participants in the control group will receive standard medical treatment for atrial fibrillation as prescribed by their attending physicians, without enhanced external counterpulsation or structured cardiac rehabilitation. This may include pharmacological therapy, routine clinical monitoring, and general lifestyle advice.

Study summary

This is a prospective randomized controlled trial designed to evaluate the effectiveness of enhanced external counterpulsation (EECP) combined with cardiac rehabilitation in patients with atrial fibrillation. The study aims to assess whether this combined intervention can improve cardiac function and exercise capacity compared to standard care alone. Eligible participants will be randomly assigned to receive either the EECP plus cardiac rehabilitation program or routine treatment. Primary outcomes include changes in left ventricular ejection fraction (LVEF) and six-minute walking distance (6MWD). The study will be conducted at Lanzhou University Second Hospital.

Eligibility

Sex
ALL
Min age
40 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Age between 40 and 80 years * Diagnosed with persistent or paroxysmal atrial fibrillation, confirmed by ECG or Holter * Stable medical condition and able to participate in cardiac rehabilitation and EECP therapy * Provided written informed consent Exclusion Criteria: * Recent acute myocardial infarction, unstable angina, or decompensated heart failure within the past 4 weeks * Severe valvular heart disease or left ventricular ejection fraction \<30% * Severe peripheral vascular disease or deep vein thrombosis * Severe pulmonary disease or active infection * History of bleeding disorders or contraindications to EECP * Cognitive impairment or psychiatric condition affecting study participation * Participation in another clinical trial within the past 3 months

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Lanzhou University Second Hospital Lanzhou Gansu

More Lanzhou University Second Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07058987 on ClinicalTrials.gov ↗ ← All trials in China